Metropolitan Life Insurance Company (MetLife)’s Alaunos Therapeutics TCRT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-172
| Closed | -$28.1K | – | 2651 |
|
|
2021
Q4 | $28.1K | Sell |
172
-27
| -14% | -$5.93K | ﹤0.01% | 2740 |
|
|
2021
Q3 | $54.4K | Sell |
199
-195
| -49% | -$59.6K | ﹤0.01% | 2748 |
|
|
2021
Q2 | $156K | Sell |
394
-5
| -1% | -$2.33K | ﹤0.01% | 2326 |
|
|
2021
Q1 | $215K | Sell |
399
-1
| -0.3% | -$623 | ﹤0.01% | 1970 |
|
|
2020
Q4 | $151K | Sell |
400
-10
| -2% | -$3.98K | ﹤0.01% | 2128 |
|
|
2020
Q3 | $155K | Sell |
410
-40
| -9% | -$17.7K | ﹤0.01% | 1939 |
|
|
2020
Q2 | $221K | Buy |
450
+171
| +61% | +$76.2K | ﹤0.01% | 1729 |
|
|
2020
Q1 | $103K | Sell |
279
-2
| -0.7% | -$1.03K | ﹤0.01% | 2014 |
|
|
2019
Q4 | $199K | Sell |
281
-81
| -22% | -$55.7K | ﹤0.01% | 1934 |
|
|
2019
Q3 | $232K | Buy |
362
+52
| +17% | +$41.3K | ﹤0.01% | 1776 |
|
|
2019
Q2 | $271K | Buy |
310
+11
| +4% | +$7.56K | ﹤0.01% | 1683 |
|
|
2019
Q1 | $173K | Buy |
299
+3
| +1% | +$1.25K | ﹤0.01% | 2000 |
|
|
2018
Q4 | $83.1K | Hold |
296
| – | – | ﹤0.01% | 2386 |
|
|
2018
Q3 | $142K | Hold |
296
| – | – | ﹤0.01% | 2238 |
|
|
2018
Q2 | $134K | Buy |
296
+24
| +9% | +$15.2K | ﹤0.01% | 2172 |
|
|
2018
Q1 | $160K | Buy |
272
+48
| +21% | +$29.9K | ﹤0.01% | 2034 |
|
|
2017
Q4 | $139K | Buy |
+224
| New | +$161K | ﹤0.01% | 2121 |
|
|
2017
Q3 | – | Sell |
-591
| Closed | -$552K | – | 2524 |
|
|
2017
Q2 | $552K | Hold |
591
| – | – | ﹤0.01% | 1619 |
|
|
2017
Q1 | $562K | Buy |
591
+25
| +4% | +$23.3K | ﹤0.01% | 1574 |
|
|
2016
Q4 | $454K | Sell |
566
-32
| -5% | -$28.8K | ﹤0.01% | 1800 |
|
|
2016
Q3 | $505K | Buy |
598
+1
| +0.2% | +$804 | ﹤0.01% | 1700 |
|
|
2016
Q2 | $492K | Buy |
597
+60
| +11% | +$65.3K | ﹤0.01% | 1714 |
|
|
2016
Q1 | $597K | Hold |
537
| – | – | ﹤0.01% | 1480 |
|
|
2015
Q4 | $669K | Hold |
537
| – | – | 0.01% | 1438 |
|
|
2015
Q3 | $726K | Hold |
537
| – | – | 0.01% | 1380 |
|
|
2015
Q2 | $966K | Buy |
537
+65
| +14% | +$101K | 0.01% | 1311 |
|
|
2015
Q1 | $762K | Buy |
472
+70
| +17% | +$104K | 0.01% | 1359 |
|
|
2014
Q4 | $306K | Hold |
402
| – | – | ﹤0.01% | 2116 |
|
|
2014
Q3 | $159K | Hold |
402
| – | – | ﹤0.01% | 2524 |
|
|
2014
Q2 | $243K | Hold |
402
| – | – | ﹤0.01% | 2365 |
|
|
2014
Q1 | $276K | Hold |
402
| – | – | ﹤0.01% | 2252 |
|
|
2013
Q4 | $262K | Hold |
402
| – | – | ﹤0.01% | 2280 |
|
|
2013
Q3 | $238K | Buy |
+402
| New | +$181K | ﹤0.01% | 2286 |
|
Other funds holding TCRT
MP
DCM
N
Metropolitan Life Insurance Company (MetLife)'s TCRT Position: Q1 2022 in Review
Metropolitan Life Insurance Company (MetLife) sold out of Alaunos Therapeutics (TCRT) in Q1 2022, closing a stake of 172 shares — an estimated $28.1K sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in TCRT in Q3 2013 and held it in 33 quarters. The position peaked at $966K in Q2 2015. 148 funds tracked by Wall St. Rank hold TCRT as of Q1 2022.
- Metropolitan Life Insurance Company (MetLife) reported no remaining Alaunos Therapeutics position as of Q1 2022 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 172 Alaunos Therapeutics shares in Q1 2022, an estimated $28.1K.
- Metropolitan Life Insurance Company (MetLife) first reported a position in Alaunos Therapeutics in Q3 2013 and held it in 33 quarters.
- Metropolitan Life Insurance Company (MetLife)'s Alaunos Therapeutics position peaked at $966K in Q2 2015.
- 148 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2022.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2022, filed 12 May 2022.